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In the UK, almost 20 000 people die each year from colorectal
cancer. Despite a potential curability rate of 70% or greater, the
overall survival at 5 years is just over 30%; a figure that has
changed little over the last 4 decades despite advances in adjuvant
and therapeutic chemotherapy and radiotherapy (King's Fund
Forum, 1990).
Moreover, there is evidence that over half the patients operated
upon for cure have occult metastatic disease at the time of initial
surgery (August et al, 1994). Recent novel immunocytochemical
techniques using immunobead polymerase chain reaction (PCR)
for detection of the tumour-associated antigen carcinoembryonic
antigen (CEA) have permitted the identification of single malig-
nant cells in peripheral blood samples, bone marrow aspirates and
peripheral stem cell harvests through the recognition of unique
hybrid gene transcripts. (Schlimok et al, 1990; Lindeman et al,
1992; Hardingham et al, 1993; Johnson et al, 1995).
Although the presence of such cells in the bone marrow at the
time ofpreliminary colon resection appears to be associated with a
worse prognosis (Riethmuller and Johnson, 1992) the number of
cells that correlates with a poor outcome is unknown, and the rela-
tionship between the development ofsecondary disease and circu-
lating tumour cells remains poorly understood (Osborne et al,
1991). Phage cloning and hybridization have taken advantage of
the limited but specific genetic alterations in developing large
bowel neoplasms to detect ras mutations in colorectal cancer cells
in the stool (Sidransky et al, 1992). The demonstration of small
tumour burdens of this type in which cells are exposed in
unshielded mesenchymal locations may provide relatively novel
immunotherapeutic and chemoimmunotherapeutic targets and
identify surrogate end points in treatment that may prove superior
to crude survival time.
Immunotherapeutic strategies in advanced colorectal cancer
have generally met with little success. Conventional treatments
have largely relied on either interleukin 2 (IL-2) or adoptive IL-2-
stimulated tumour infiltrating lymphocytes (TILs), with only
sporadic reports of tumour regression (Rosenberg et al, 1989;
Kradin et al, 1989). Recently, there has been a resurgence of
interest in immunotherapy (and the potential of gene therapy) in
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advanced colorectal cancer and in an adjuvant setting. The adju-
vant use ofthe murine monoclonal IgG2a antibody, 17- A directed
against the CO 17-1A surface epitope of CEA (found in up to
80% of colorectal carcinomas) has resulted in an improvement in
disease-free survival and a reduction in locoregional recurrence
rates of almost 30% in patients with Dukes' C carcinoma
compared with untreated controls (Riethmuller et al, 1994).
Carcinoembryonic antigen (CEA), a surface-expressed tumour-
associated antigen, is a well-characterized glycoprotein repre-
sented in high density on most malignant tumours of the
gastrointestinal tract (Muraro et al, 1985). The immunogenicity of
CEA as a potential target antigen in colorectal cancer is at present
unclear, with variable reports of inducible humoral and cell-
mediated responsiveness to CEA epitopes in patients with
different stages of disease. There is much that remains unknown
regarding the natural immunological response to a native antigen
such as CEA both in terms of its antigenic processing and its
potentially immunodominant epitopes.
This review assesses the role ofCEA as a 'natural' autoantigen
along with strategies that render epitopes of CEA potentially
immunogenic. This may be achieved by the use of xenogeneic,
chimaeric, humanized or wholly human monoclonal and poly-
clonal antibodies and with anti-idiotypic therapy. The advantages
and limitations ofeach strategy and theirpotential role in the treat-
ment ofadvanced colorectal cancer are discussed.
MECHANISMS OF TUMOUR ESCAPE FROM
IMMUNOLOGICAL RECOGNITION
The variability of tumours permits their escape from immune
recognition. An improvement in the understanding ofthe immuno-
biology of cell-mediated anti-tumour defences as well as a better
knowledge of tumour recognition molecules expressed on the
surface of many tumours has permitted the development of
new anti-tumour strategies to stand alongside conventional
chemotherapy and radiotherapy in colorectal cancer.
Isolated tumour cells are able to be eliminated by several
conventional immunological mechanisms, most notably antibody
dependent cellular cytotoxicity (ADCC) (Steplewski et al, 1983;
Adams et al, 1984) complement-dependent cytolysis (Herlyn
and Koprowski, 1981) and apoptosis (Trauth et al, 1989).
Knowledge of cell surface regulatory molecules expressed on
tumour cells may enhance natural apoptosis and tumourregression
(Wyllie et al, 1980).
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Figure 1 Mechanism of MHC molecule antigen processing. (A) Class 1 MHC antigen processing. Proteasomes digest cytoplasmic protein into processed
peptides (eight or nine amino acids in length). These peptides adhere to the endoplasmic reticulum by polymorphic transporter proteins (Tap-1 and Tap-2).
Chaperonin molecules detain empty MHC class molecules in the endoplasmic reticulum for association with processed antigen and transfer to the cell surface.
(B) Class II MHC antigen processing. Foreign antigen is endocytosed and after processing (peptides 15-25 amino acids in length), the peptide is aggregated in
the Golgi apparatus with a, f and ycomponents of the MHC class II molecule formed in the endoplasmic reticulum. After complexing with foreign peptide, the y-
chain is degraded and the ax1 heterodimer/processed antigen is expressed on the cell surface for Th TcR recognition. The mechanism of transport of the
complex from the Golgi apparatus to the cell membrane is unknown
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Figure 2 Mechanism of T-cell receptor (ac) complex interaction with
antigen presenting cell. T cells have a dual specificity for MHC molecules and
processed antigen. The TcR aJ is complexed with CD3, which has an
intracytoplasmic component for signal transduction after occupancy with
processed antigen. The CD4 molecule secondarily interacts with MHC class
11 to produce local cytokines (IL-2 and IFN-y) for Th cell support and
transformation of B cells. CD 28 initiates signal transduction independently to
augment local cytokine production using B7 as a ligand molecule
The finding of unique tumour-associated antigens (TAAs) in
solid malignancies has presented a range of important targets for
adoptive humoral and cellular immune therapies. Early attempts to
define TAAs in murine models by immunizing mice against either
spontaneous tumours or chemically and virally induced tumours
were confused by general species reactivity to normal transplanta-
tion antigens. The development of syngeneic mice with identical
histocompatibility antigen expression systems permitted cuta-
neous but not tumour transplantation, implying the presence of
tumour-specific antigenicity. Most work on tumour immunology
has centred on cytotoxic T-cell (CTL) activity since the demon-
stration that the ability to reject tumours can be adoptively trans-
ferred by lymphocytes and not by serum.
The recognition offoreign tumour antigens requires a presenta-
tion to immunocytes in the form of target fragments linked to the
major histocompatibility complex (MHC) class I and class II
molecules interacting with the T-cell receptor (TcR) mechanism.
Intracellular antigens, such as oncogene products and extracellular
(or foreign) antigens, are handled differently by the immune
system with the development ofparallel but separate mechanisms
for dealing with these foreign challenges. Intracellular antigens
produce processed peptides (usually eight or nine amino acids
in length), which are generally presented to CD8+ cells (T-
suppressor/cytotoxic lymphocytes) by MHC class I molecules.
Extracellular antigen is processed for presentation as 15-25 amino
acid length peptides to CD4+ cells (T-helper cells) by the MHC
class II molecules found on specialized (so-called professional)
antigen-presenting cells, such as dendritic cells, macrophages
or B lymphocytes. The mechanisms of MHC-restricted antigen
processing are shown in Figure 1.
Figure 2 shows the complex activation process of the T cell
receptor.
Tumour cells have developed several mechanisms to inhibit
immunological attack for survival advantage in hostile locations.
The failure of a tumour to induce a specific rejection response
may partly be a result of the poor expression of foreign TAAs,
such as CEA. Knowledge ofthe intricate mechanisms involved in
foreign antigen presentation has permitted the development of
potential genetic targets to overcome heterogeneity of surface
antigen expression. The discovery of co-stimulatory signals has
created a model of lymphocyte and specifically TcR activation
(Bretscher and Cohn, 1970), whereby processed antigen may be
linked either to the MHC complex or to a co-stimulatory ligand in
its presentation to the T cell.
Co-stimulatory signals implicated in the activation of the TcR
include tyrosine kinases, interleukins, the B7 family (Chen et al,
1993), the ICAM group, lymphocyte function-associated antigens,
vascular cell adhesion molecules (VCAM-1) and heat stable anti-
gens (HSA).
Studies of immunological tolerance have also assisted in the
understanding of mechanisms of tumour escape from immune
British Journal ofCancer (1998) 77(5), 683-693 0 Cancer Research Campaign 1998Biological therapy: approaches in colorectal cancer 685
surveillance and lysis. The exposure of both the T- and the B-cell
lineage to TAAs may result in clonal selection, with proliferation
of immunocompetent effector cells, clonal anergy with down-
regulation of immunogenic capacity or effector maturation arrest
(Nossal and Pike, 1980; Goodnow et al, 1991). The concept of a
population of down-regulated T- and B-cell repertoires with a
threshold affinity for silencing was advanced by Nossal (1983) as
one of 'immune ignorance'. T-cell tolerance of this type, which is
part of normal thymocyte maturation of medullary CD4+ and
CD8+ cells, permits the acquisition ofTcR molecules with a high
affinity for self-MHC and self-epitope recognition (Miller and
Moralan, 1992; Shortman, 1992). How important this model is,
however, outside in vitro systems is notknown. Immuneignorance
as opposed to T-cell deletion or anergy appears to be a more
complexphenomenon and is secondary to a differential inability of
lymphocytes in the periphery to recognize antigenic motifs in
restricted tissue sites.
B-cell tolerance is clearly physiologically important too, as it
prevents the development of a range of naturally produced auto-
antibodies against cross-reactive self-epitope. This type of auto-
antibody phenomenon, although common, is fortunately transient.
The decision between clonal anergy and clonal ignorance is prob-
ably dependent upon the affinity of the B-cell receptor for the
antigen concerned as well as the antigenic molar concentration.
Anergy is favoured in states of very high antigen concentration,
strong antigen cross-linking and high antibody affinity.
Widespread extracellular antigen expression (of CEA, for
example) may therefore havealready induced substantial T- and B-
cell tolerance of the types mentioned. As a result, any anti-tumour
vaccine based upon a native protein needs to either couple the
epitope for recognition with another highly immunogenic carrier
molecule (a so-called adjuvant) or use secondary strategies to
enhance its immunogenicity.
Intratumoral variation may also provide an avenue for tumour
escape from immunological attack. Previously, the main markers
for tumour heterogeneity were morphological, biochemical and
karyotypic, but increasingly there is recognized to be both
molecular biological and immunohistochemical variability within
tumour cell subpopulations that may affect immunotherapeutic
andchemotherapeutic response. The multistep nature ofcolorectal
carcinogenesis postulates potential mechanisms for intratumoral
heterogeneity. At its simplestlevel, differences in tumour differen-
tiation and tumour DNA ploidy may be reflected in differences in
outcome. Tumour aneuploidy has been shown to correlate with
overall prognosis in ovarian, renal cell, thyroid, adrenal and breast
cancer (Rodenburg et al, 1987; Hamming, 1988; Oosterwijk et al,
1988; Haak et al, 1993; Hedley et al, 1993).
Finally, tumour heterogeneity may be a reflection of the under-
lying host immune defence systems. Potential mechanisms for
immunological escape by tumour cells include changes in the
structure of crucial molecules, such as MHC activation ligands,
regulators ofcomplementactivation, lytic enzyme neutralizers and
adhesion molecule receptors.
Disturbances in B-cell-mediated responsiveness may occur
through other mechanisms, such as insufficient neoantigen
presentation, relative immunological isolation (in areas such as the
central nervous system or in ocular tumours), tumour-produced
suppression by local inhibitors (prostaglandins and transforming
growth factor beta) and drug-induced immunosuppression. In this
sense, the immune system contributes to the phenotypic hetero-
geneity ofthe tumour.
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Figure 3 Representation of the carcinoembryonic antigen family. Ig-like
domains are shown as ribbons. The black N domain is 1g v-like and the
striped domains are 1g C-like. Ig C regions are repeated extracellularly into
discrete domain regions A1-3 and B1-3. In the CEA molecule the membrane
attachment is by a glycosyl phosphatidyl inositol anchor. Biliary glycoproteins
(BGP) are membrane attached by a hydrophobic transmembrane region with
a relatively long intracytoplasmic tail for signal transduction. Pregnancy-
specific globulins (PSG) are actively secreted from the cell. GPi, glycosyl
phosphatidyl inositol hook; Tm, ... transmembrane attachment
CEA AS AN IMMUNOGENIC TARGET:
STRUCTURE AND FUNCTION
Knowledge ofthe molecular structure of CEA defines recognition
epitopes as immunological targets and assists in the design of
monoclonal antibody therapy directed against cell-based TAA.
This is particularly important in a molecule such as CEA, in which
extensive carbohydrate moieties mask epitopes.
Molecular cloning at the cDNA level has permitted the identifi-
cation ofat least 29 CEA-related genes that are tightly clustered on
a 1.2-Mb region located on the long arm of chromosome 19
(Tynan et al, 1992).
Comparisons of related family members have shown high
sequence conservation (80-95% of N domain exons within
subgroups and 65-70% homology between subgroups). The CEA
gene along with that fornon-specific cross-reacting antigen (NCA)
and the biliary glycoproteins (BGP) comprise the CEA subgroup
and the pregnancy-specific globulins (PSG) the other group of
related genes. The basic common domain structure of the CEA
subgroup (Figure 3) incorporates a variable number of internal
repeating subunits that have equivalent secondary and tertiary
structure to the immunoglobulin C2 domains. The N domain ofthe
molecule is structurally homologous, with the immunoglobulin V-
like domain rendering the CEA family within the immunoglobulin
superfamily of molecules (Williams and Barclay, 1988).
CEA is attached to the cell membrane by a glycosyl phospha-
tidylinositol (GPi) hook that is structurally distinct from the trans-
membrane attachment ofthe PSG group memberproteins (Hefta et
al, 1988; Thompson and Zimmerman, 1988; Ferguson, 1991;
Thompson et al, 1991).
The homology of CEA with basic immunoglobulin molecules
gives a clue as to the functional role of CEA-related antigens.
Those containing C2 domains are involved in cell adhesion. CEA-
transfected cells have been shown to have adhesive properties
through both homophilic and heterophilic interactions. Selective
binding between carbohydrate moieties on CEA and lectin mole-
cules on bacterial fimbriae may permit CEA to regulate gut-
bacterial binding and control lymphocyte homing during gut
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inflammation (Leusch et al, 1990). As a result, the regular luminal
shedding of CEA may serve to control luminal bacterial load and
translocation across the gut.
Many studies with regard to differential expression of CEA-
related proteins during development have been produced in animal
models that do not normally possess endogenous CEA-like
species. The specificity of both polyclonal and monoclonal anti-
bodies to CEA for immunohistochemistry has been enhanced by
the use of cDNAs in expression vector systems producing a series
of stable transfectant eukaryotic clones expressing most of the
major CEA-related protein products (Arakawa et al, 1990; Berling
et al, 1990; Hefta et al, 1990).
Over 50% of the CEA molecule is glycosylated with at least 28
separate putative sites of carbohydrate attachment. The position
and density ofthese sites affect the exposure ofpotential antigenic
recognition surfaces and, because ofthe heavy glycosylation ofthe
molecule, crystallization for diffraction studies and structure inter-
pretation have been difficult (Bates et al, 1992). Knowledge of
these binding sites will permit the engineering of antibody mole-
cules and other immune targeting agents based on CEA epitope
structure that have slower offrates and that facilitate tumour reten-
tion by the antibody molecule (Boehm et al, 1996).
Limitations should be placed on extrapolation of data regarding
the inherent immunogenicity of CEA within such models. For this
work, it has been necessary to introduce CEA gene-regulatory plus
indicator segments into transgenic mice as well as to produce gene
inactivation by homologous recombination in induced colonic
tumours that subsequently express human CEA (Eades-Pemer and
Zimmerman, 1995).
Recently, the novel anti-CEA monoclonal antibody PR1A3 has
been successfully used in radioimmunoscintigraphy for the detec-
tion of CT-negative and CEA-negative recurrent colorectal cancer
as well as to investigate the cell-based epitope domain of CEA
(Granowska et al, 1989, 1993; Durbin et al, 1994). This antibody
was originally produced in mice against components of normal
human colonic epithelium and has been demonstrated to be highly
sensitive by immunohistochemistry for nearly all human colorectal
carcinomas, regardless of differentiation. It is highly specific with
only minor cross-reactivity in normal respiratory epithelium
(Richman and Bodmer, 1987). The significance of this antibody is
its inability to bind circulating and purified CEA or CEA released
from tumours and sequestered in lymph nodes. This epitope is not
expressed by bacteria transfected with CEA fusion genes, implying
the importance ofpost-translational modification and/or conforma-
tional changes in CEA once shed. The use ofCEA-BGP chimaeric
peptides has localized the PR1A3 epitope to the C terminus of the
protein and binding is entirely reliant upon the presence of a small
spacing peptide between the GPi anchor mechanism and the BGP
recombinant construct (LM Stewart and D Snary, personal
communication). This spacing peptide is believed to lift the B3
domain away from the cell membrane and permit antibody binding
to the epitope. The exact mechanism ofabrogated binding to circu-
lating antigen is unknown, but may involve partial domain loss, the
formation of steric hindrance by dimers of CEA or disruption of
the epitope on release from the cell.
Immunotherapeutic strategies making use of murine (and
humanized) PR1A3 will have the advantage ofproviding surrogate
responses to cell-based TAA, avoiding circulating complex
formation. At present, a phase I/HI trial using murine PR1A3
in chemo-relapsed colorectal cancer has commenced at our
institution.
HUMORAL AND CELL-MEDIATED RESPONSES
TO CEA
There is conflicting evidence that CEA functions as a natural
immunogen in patients with advanced epithelial malignancy. It has
traditionally been supposed that CEA is likely to have induced
a state of tolerance and that this is compounded by the
relative anergy evident in patients with advanced disease
(Monson et al, 1986).
Some studies have consistently demonstrated the presence of
circulating specific anti-CEA antibodies by indirect haemaggluti-
nation (Gold, 1967), radioimmunoassay (Gold et al, 1972;
MacSween, 1975) and affinity chromatography (Pressman et al,
1980). Moreover, specific immune complexes directed against
CEA, when present, have been shown to inversely correlate with
overall survival and disease stage (Kapsopulou-Dominos and
Anderer, 1979; Staab et al, 1980; Mavligit et al, 1983; Ura et al,
1985; Konstadoulakis et al, 1994). Other groups (Collatz et al,
1971; LoGerfo et al, 1972; Sorokin et al, 1973) have been unable,
however, to demonstrate CEA-specific antibodies in the sera
of patients with different gastrointestinal neoplasms. Very early
studies have shown CEA as non-stimulatory for autologous
lymphocytes in in vitro blastogenesis assays (Lejtenyi et al, 1971;
Hollinshead et al, 1972; Mavligit et al, 1973a), although these
reports are difficult to interpret as there are a mixture of potentially
anergy-inducing factors inherent in these experiments. Differences
in tumour antigen extraction technique, inactivation of CEA
during the extraction process and the potential need for presensi-
tized lymphocytes in stimulation assays may all affect the outcome
of results (Mavligit et al, 1973b).
Recently, molecular cloning techniques have identified a range
of tumour-specific peptides (largely in malignant melanomas)
that are recognized by autologous MHC-restricted human T cells.
It is uncertain whether these peptides are actually normally
processed in vivo or whether cytotoxic-specific T-cell repertoires
to these agents naturally exist (Slingluff et al, 1993; Wolfel et al,
1994).
Given the recent evidence of natural CTL reactivity against the
normal tyrosinase enzyme system in melanoma patients, it is likely
that CEA may be sufficiently immunogenic either alone or anti-
genically enhanced to function as a cancer vaccine (Anichini et al,
1993). Similar MHC-restricted CTLs have been demonstrated in
ovarian and renal carcinoma, sarcoma, squamous cell carcinoma
ofthe head, neck and lung and glioblastoma (Miyatake et al, 1986;
Slovin et al, 1986; loannides et al, 1991, 1993; Finke et al, 1992).
It remains unclear why natural tolerance to these peptides is
not fully established or why T cells become reactive to self
peptides on melanoma, for example, but the same peptides are not
recognized by the lymphocytes of patients bearing other cancer
histologies.
The potential options for using CEA as a direct immunizing
antigen include the use of recombinant vaccinia virus-CEA
constructs, polynucleotide CEA vaccination and anti-idiotypic
antibodies. Secondary strategies rely on recombinant CEA and
CEA-derived peptide booster therapy to maintain specific anti-
CEA response.
RECOMBINANT VACCINIA CEA (rV-CEA)
The strategy here is that arelatively weak immunogen is presented
with a highly immunogenic viral protein and that the resultant
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immune reaction is directed in part against the inserted gene
product (Kaufman et al, 1991).
The insertion of stable eukaryotic genes into vaccinia vectors is
only a recent development (Edwards and Rutter, 1988). The
vaccinia virus is capable of co-presentation of antigen, and
constructed vaccinia viruses have been shown to protect animals
against infectious disease and tumour challenges (Bennick et al,
1984; Moss et al, 1984; Bernards et al, 1987; Lathe et al, 1987;
Moss and Flexner, 1987; Estin et al, 1988). It has been shown that
vaccinia virus vectors are stable and that inserted gene products
from human colon cancercell libraries are expressed and normally
post-translationally modified (Coupar et al, 1988). Preliminary
work has shown the induction in mice of specific anti-CEA anti-
bodies, with reduction in the growth pattern of syngeneic murine
colon carcinoma deposits transduced with the human CEA gene.
RV-CEA also induces CEA-specific lymphoproliferative and
CTL responses as well as delayed-type hypersensitivity reactions.
(DTH) (Kantor et al, 1992a). The virus insert approach has also
been successfully used in mouse and primate tumour models
against the melanoma-associated antigen p97, which is weakly
expressed on normal cells, and this has resulted in subsequent
protection against tumour challenge with cells expressing the
human p97 gene product (Estin et al, 1988; Hu et al, 1988).
Recombinant vaccinia (and other virus) products will not be
perfect, however, as there are cross-reactive epitopes forCEA-like
species, such as NCA, normally expressed on human (andprimate)
granulocytes. The hope for clinical use is that immune responses
principally occur to the immunodominant epitope located on CEA
and that immunotolerance may be greater to the more widely
distributed NCA antigen (Nap et al, 1988).
The results of the use of this approach in a rhesus monkey
model that displays primate MHC and in which NCA cross-
reacting antigen is expressed on normal monkey granulocytes
show that it induces proliferative DTH response to intradermal
challenge with CEA, proliferative blastogenesis to CEA and also
primate-directed antibody-induced lysis of CEA-bearing tumour
cells using human effector lymphocytes. The treatment has been
shown to be relatively free ofside-effects (Kantor et al, 1992b). In
humans, recombinant vaccinia viruses havebeen shown to be safe,
stable and to have acceptable immunogenicity, even when the
individual has been previously exposed to a vaccinia virus as
occurs after routine smallpox vaccination (Karzon, 1985;
Chelyapov et al, 1988).
A phase I clinical trial has been reported by Hamilton et al
(1994) in 26 patients with gastrointestinal, lung and breast cancers
using lO1 plaqueforming units (p.f.u.) ofrV-CEA atmonthly inter-
vals for 3 months. T-cell responses to the vaccinia virus were
observed, but there was no response to soluble CEA in blasto-
genesis assays.
Canarypox (Avipox group) has also been engineered to express
the human cDNA ofCEA. This virus is restricted, however, in its
replication hosts, although it is likely to result in enhanced
immunoresponsiveness in those patients previously exposed to
smallpox vaccination or when local reactivity to repeated rV-CEA
proves to be unacceptable (Hodge et al, 1997).
Antigenic peptides reflecting potential class I epitopes of CEA
have recently been selected by screening for matches to consensus
motifs ofHLA-A2 and A3 binding peptides as the mostcommonly
expressed HLA alleles. The CEA peptides (so-called CAP
peptides) identified have been incubated in a T-cell binding assay
in which up-regulation of surface HLA-A2 on the T cells was
quantified by flow cytometry using an anti HLA-A2 antibody label
(Nijman et al, 1993).
Specific T-cell lysis has been generated against autologous
EBV-transformed B cells presenting the CAP-I peptide motif but
not against autologous non HLA-A2 EBV-transformed B cells
pulsed with the same peptide. Tumourcell lysis oflines transduced
with CEA serve as targets for these effector cells, implying that
autologous B cells present and process these antigens in an
MHC-restricted fashion. Allogeneic SW403 HLA-A2-positive cell
lines also expressing CEA function as equivalent targets and non
HLA-A2 allogeneic carcinoma cell lines (SW 1417 and HT-29)
that do not express substantial CEA are not lysed. This is the first
study to demonstrate peptide based CEA-specific CTLs and
evidence of MHC-restricted CEA epitope processing by B cells.
(Conry et al, 1995a).
This type oftherapy still requires substantial work. The impor-
tance of non-human CEA-like and human CEA-transduced
systems in natural immunity is unclear. Epitopes that are immuno-
logically relevant in tumour biology must be able to be stably and
consistently coexpressed with dominant immunogenic viral
peptides. Tachyphylaxis associated with such approaches still
needs to be overcome, but it is evident that troublesome cross-
reactivity does not appear to be a clinical problem.
CEA POLYNUCLEOTIDE VACCINATION
This form of active specific immunotherapy may be provided by
both DNA and RNA and has certain advantages over tumour cell
vaccines. It avoids potentially replicating virus and the need for
adjuvants and appears stable in terms of gene product expression
and induction of CEA-specific T-cell repertoires. Intracellular
synthesis ofthe TAA favours MHC class I display and large quan-
tities ofthe vaccine can in theory beproduced and standardized for
clinical use (Wolffet al, 1992; Conry et al, 1994, 1995b, 1996a).
The use ofthis form ofimmunization avoids potential recombi-
national events that may produce replication-competent viruses or
the inadvertent incorporation of viral genomes into the host chro-
mosomal complement. Both of these events may have serious
consequences from the standpoint of the activation of oncogene
sequences. The direct delivery of naked DNA therapy will also
reduce the likely event ofinsertional mutagenesis. Polynucleotide
vaccination uses the full length ofh CEA cDNA driven by a CMV
promoter and induces anti-CEA humoral and CEA-lymphoprolif-
erative responses in mice. It has not been shown, however, to
result in murine protection against syngeneic challenge with CEA-
transduced colorectal cancer cells, unless administered by the
intramuscular route. Stable gene expression systems use murine
intramuscularplasmid injection, and DNA-coated bead projectiles
have also been developed (Wolffet al, 1990; Yang et al, 1990).
The level of immune responsiveness with DNA vaccination
appears equivalent to that induced by rV-CEA, although there
is greater dose and schedule dependency. The amounts of gene
gun dosage required appear to be minute (Eisenbraun et al, 1993;
Pertmer et al, 1997).
The system of direct intramuscular plasmid injection needs
improvement as mouse myocytes expressing CEA tend to die after
about 10 days. The mechanism whereby the mouse myocyte func-
tions as a semiprofessional antigen presenting cell is at present
unknown, however myocytes have been shown to up-regulate
MHC expression aftery-interferon stimulation, and their immuno-
stimulant capacity is enhanced by co-transfection with B7
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Figure 4 The immune network in tumour biology. A range of anti-idiotypic
antibodies are produced in response to the AB, molecule. Ab2p antibodies
recognize the antigen binding site ofAb1 and are 'internal images' of the
epitope. Ab2a antibodies recognize idiotopes that lie outside the antigen
binding site of Ab,. Ab2yantibodies recognize a portion of the antigen binding
site of Ab, but do not carry the internal image of the antigen. An idiotype
cascade results in the production of Ab3 antibodies that resemble Ab, in their
binding site sequence and that secondarily recognize the antigen
Table 1 Techniques to enhance monoclonal antibody tumour targeting
Strategies to enhance tumourlocalization
Vascular endothelial monoclonal antibodies
New labelling techniques
Different antibody isotypes
Genetically engineered antibodies
High-affinity antibodies
Unlabelled antibody pre-dosing
Antibody cocktails
Fractionation
Strategies to increase radioimmunoconjugate clearance
Antibody fragments
Pre-targeting approaches
Metabolizable chelates
Second-clearing antibodies
Plasmapheresis
Otherlocalizing strategies
Regional administration
Biological-response modifiers to increase TM expression
Increases in tumour vascularity
plasmids, suggesting a role as formal antigen presenters (Goebels
et al, 1992; Hohlfield and Engel, 1994; Conry et al, 1996b). It may
be that an inflammatory response against the plasmid construct
evokes a secondary recruitment ofprofessional antigen-presenting
and other effector cells.
Successful CEApolynucleotide vaccination strategies havenow
been conducted in non-human primates (Wang et al, 1993). An
initial phase I dual-specific plasmid DNA (CEA and hepatitis B
surface antigen) study in patients with metastatic colorectal cancer
has recently been jointly approved by the Recombinant DNA
Advisory Committee and the NIH in the USA (Conry et al,
1996c). The use ofnaked mRNA vaccination offers several advan-
tages when injection ofDNA potentially encoding tumour growth
factors risks incorporation of delivered genetic material into the
host genome. This approach has been used with CEA mRNA
transcripts transfected into CEA-negative cell lines using cationic
liposome vectors. In this instance, the immunization schedule to
maintain CEA expression needs to be more intensive than that
usedfornaked DNA. Mostmice, however, develop anti-CEA anti-
body responses when challenged with CEA-expressing tumour
cells. Work is progressing using single-stranded RNA vectors for
eukaryotic transfection that undergo self-replication after trans-
duction but that are non-infectious (i.e. they do not contain the
gene regions encoding viral-packaging proteins). So far, represen-
tatives of the Togaviridae have been used, notably poliovirus,
Semliki Forest virus and Sindbis virus (Ansardi et al, 1994; Conry
et al, 1995c; Zhou et al, 1995).
The in vivo delivery ofplasmid DNA encoding a relevant TAA,
although immunologically effective in animal models, has several
problems in humans. The principal difficulty is the reduced effi-
ciency of non-human primate and human expression of plasmid
DNA in muscle (Jiao et al, 1992). This may require the co-delivery
of either a cytokine gene or co-stimulator cDNA for enhancement
of the CEA polynucleotide.
DESIGNER MONOCLONALS, ANTI.IDIOTYPIC
ANTIBODIES AND COLORECTAL CANCER
Jerne's proposal of a cascading network of idiotype-anti-idiotype
antibodies after antigenic immunization (Jeme, 1974) has been
widely adopted as a model for the induction of V-domain inter-
actions as part of a humoral response to available TAAs. This
immune network is shown in Figure 4. The primary antibody
(Ab,) reacting with the main antigenic epitope contains compo-
nents on its V domain that function as secondary 'epitopes' and
that are recognized as antigenic by a second line ofantibody mole-
cules referred to as anti-idiotypic (Ab2) antibodies. These Ab2
molecules are serologically and stereochemically divisible into
several subgroups: Ab2a molecules, which identify idiotopes
outside the antigen binding site; Ab203 molecules, which function
as internal images of the original antigen; and Ab2y molecules,
which are capable of partial antigen/Ab1 blockade but which are
not antigenic internal images. Anti-idiotypic antibodies potentially
induced by TAA exposure may serve as natural agents for use in
passive immunotherapy because oftheir ability to act as surrogate
antigen vaccines, being capable of stimulating anti-anti-idiotypic
antibodies (designated as Ab3), which functionally mimic the
steric structure of the Ab1 molecule and which directly attack the
primary antigen.
Such anti-idiotypic cascades are involved in immune regulation
in several ways. Ab2 antibodies are capable of neutralizing circu-
lating Ab1 as well as binding to surface immunoglobulin receptors
on activated B cells, thus interfering with TcR function and T-/B-
cell interaction.
Monoclonal antibodies are used in patients with colorectal
cancer for radioimmunolocalization of recurrent or metastatic
disease, in radioimmunoguided surgery and as specific
immunotherapy, inducing anti-idiotypic cascades and CTL reac-
tivity when directed against well-characterized epitopes of CEA.
The latter approach is undergoing a revolution with the use of
humanized and bifunctional antibodies, F(ab') and single Fv frag-
ments as well as withhuman anti-idiotypic antibodies. In addition,
therapies may be conjugated with toxins orradiopharmaceuticals.
There are many barriers to monoclonal antibody usage in solid
malignancy. Heterogeneity of TAA and MHC expression may
limit antibody binding. Physical factors most notably related to
distorted tumour vascular architecture and increased intratumoral
interstitial pressure limit the diffusion and biodistribution of
macromolecules to the periphery oftumour deposits.
As tumour deposits enlarge, available surface area for trans-
vascular molecular exchange diminishes in the majority oftumour
types (Jain et al, 1988). Further, as the interstitial pressure
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particularly in the centre of most tumours exceeds that of normal
tissue, convection of macromolecules through the interstitial
space, which is primarily dependent upon pressure gradients
between the vascular and extravascular spaces, will work against
the movement of antibodies towards the tumour matrix (Jain,
1987).
Approaches to overcome these difficulties are shown in Table 1.
Lower-molecular-weight fragments ofthe primary antibody or the
regional administration of antibody may improve local intra-
tumoral concentration, but are often associated with accelerated
elimination. The pharmacokinetics of these agents as well as that
of bifunctional antibodies with hypervariable murine anti-idio-
typic domains linked to TcR cell surface recognition molecules,
remains to be elucidated.
One of the greatest difficulties with the use of murine mono-
clonal antibodies is the development of a human anti-murine anti-
body (HAMA) response to the Fc portion of the primary mouse
antibody administered. The extent of this response particularly to
repeated murine exposure will limit the therapeutic effect of
monoclonal treatment, shorten antibody half-life, enhance clear-
ance of antibody and potentially induce a serum sickness reaction
in treated patients. The nature ofthe HAMA response is polyclonal
with anti-isotypic and anti-idiotypic reactivity and may even affect
the administration of human and humanized antibodies. This type
of heterophilic antibody response will also interfere with assays
that routinely use murine monoclonals, most notably standard
CEA assay (Morton et al, 1988).
The finding of significant HAMA responses has resulted in the
production of a range of designer antibodies, such as chimaeric
antibodies, VH domain molecules, antigen-binding peptides and
recombinant antibody fusion proteins (Mayforth and Quintans,
1990; Fell et al, 1991; Winter and Milstein, 1991).
Genetically engineered antibodies that lack Fc reactivity could
be used when Fc function is not desired, such as in radio-
immunolocalization to diminish background (Bird et al, 1988).
Single-chain antigen-binding fragments (sFv) and recombinant
sFv peptides, which consist of VL and VH domains joined by
peptide linkers and expressed in large quantity by Escherichia coli,
are being developed for imaging purposes, although problems
exist both with reduced affinity compared with the parent mole-
cule and steric hindrance of the linker peptides. Many of these
newer peptides are also relatively unstable. Despite chimaeriza-
tion, anti-idiotypic antibodies that recognize the murine V region
are potentially still a problem (Bruggemann et al, 1989). Although
humanization of antibodies reduces their immunogenicity, the
antigen-antibody binding affinity of the parent antibody may not
be reproduced.
Although idiotypic-anti-idiotypic cascades can be demonstrated
in patients with tumours after xenogeneic monoclonal antibody
therapy, their exact significance is notknown. The further advantage
of such immune therapy, however, in solid tumours is their relative
ease of production for general use, without the need for custom-
made therapies using autologous tumour cells or autologous-
stimulated TILs. The recent development of genetic recombinant
libraries expressing specific epitope domains that are entirely human
will enhance the ability to expand therepertoire ofimmunotherapies
against a variety of unique TAAs, with large-scale production
of antibody for use in conjunction with either conventional
chemotherapy or progenitor cell support (Bona, 1989).
One ofthe main advantages ofusing anti-idiotypic antibodies in
tumour therapy is in states in which the primary antigen is either
weakly expressed or is frankly non-immunogenic. They may, in
theory, break immune tumour tolerance to weak determinants and
be useful against antigens that are difficult to characterize or
synthesize. The use of human anti-idiotype therapy rather than
either monoclonal or polyclonal xenogeneic anti-idiotype therapy
avoids troublesome interspecies reactivity and the induction of
inappropriate and non-specific human T-cell repertoires. Human
therapies are likely to mediate more efficient complement-depen-
dent cell lysis and ADCC (Chattopadhayay et al, 1992; Koido
et al, 1995). For anti-idiotypes, the problems of oversecretion of
complexing antibody, HAMA responsiveness, the induction of
down-regulating idiotypic cascades and the difficulty of matching
bizarre tumour cell idiotopes that are not shared between tumour
types still remain. Human anti-idiotypic monoclonal therapy has
resulted in survival benefit in patients with advanced malignant
melanoma, and advanced colorectal carcinoma has demonstrated
improved outcome when compared with historical controls
(Robins et al, 199la; Mittelmam et al, 1992).
Further, CTL activity of both peripheral blood and mesenteric
node lymphocytes against autologous tumour has been demon-
strated in a small numberofpatients with rectal cancer afterimmu-
nization with human anti-idiotypic antibody when lymphocytes
did not initially respond in vitro to autologous biopsy material
(Austin et al, 1991; Durrant et al 1994a and b; Robins et al,
1991b). Similar findings producing anti-CEA antibodies have
been shown in cynomolgus monkeys using the murine anti-idio-
typic antibody 3H1, which mimics an epitope on CEA normally
absent on adult colonic epithelium (Bhattacharya-Chatterjee et al,
1990; Chakraborty et al, 1995).
There is as yet comparatively poor prediction of the relative
immunogenicity of anti-idiotypes necessary for T-cell responsive-
ness in tumour systems (Raychaudhuri et al, 1990; Tsang et al,
1995). Recently, cytokines have been used in combination with
monoclonal antibodies to enhance MHC (Rosa and Fellous, 1988)
and CEA (Kantor et al, 1989) expression as well as to improve
residual tumour radioimmunodetection (Nieroda et al, 1995).
Interferon-y has been shown to increase CO 17-1A-directed
ADCC by human effector cells against colorectal cancer cell lines
(most notably SW 116) (Steplewski et al, 1986); however, phase II
studies in patients with advanced colorectal carcinoma combining
the monoclonal antibody 17-lA with interferon-y, although
safe for clinical use, have shown inconsistent anti-idiotypic
responsiveness and poor clinical responsiveness (Blottiere et al,
1990). Granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Sieff et al, 1985), which stimulates differentiation and
maturation of the monocyte-macrophage lineage, enhances in
vitro ADCC function, stimulates delayed-type hypersensitivity
and encourages professional antigen presentation, has also been
used in combination with monoclonal antibody therapy (Morrissey
et al, 1987). Recent reports assessing its use in combination with
17-1A in advanced colorectal cancer have shown clinical remis-
sions, although the therapy is marred in some patients by the
presence of immediate-type allergic responses to the murine
monoclonal after repeated exposure. This has necessitated reduc-
tion of the monoclonal antibody dose (Raganhammar et al, 1993,
1995). Further, the ultimate development in most patients of
neutralizing anti-GM-CSF antibodies after combination therapy
may result in significant failure of the normal peripheral lympho-
cyte expansion seen during colony-stimulating factor (CSF)
treatment.
This may have a signicant bearing on the type and level of
British Journal ofCancer (1998) 77(5), 683-693 0CancerResearch Campaign 1998690 APZbar etal
sustainable immune response during monoclonal antibody treat-
ment. This is particularly evident in non-immunosuppressed
patients capable of mounting an auto-immune reaction against
endogenous colony stimulating proteins. This may render conven-
tional CSF therapy in such patients relatively ineffective (Wadhwa
et al, 1996). It is clear that unconjugated anti-idiotypic therapy
induces specific humoral and cell-mediated responses against
syngeneic and histocompatible colorectal cancer cell lines. At
present, the dosage scheduling and the need for combination ther-
apies in patients with advanced disease has yet to be determined.
Clinical responses to date are sporadic.
FUTURE STRATEGIES OF BIOLOGICAL
THERAPY AND COLORECTAL CANCER
The prospects for gene therapy in colorectal cancer include the
correction of abnormal oncogenes implicated in the development
ofcolorectal tumours, the augmentation orreplacement oftumour-
suppressor genes, such as p53, and strategies to interfere with
tumour-related growth factor and growth factor receptor genes.
Ancilliary approaches will include genetically directed
immunopotentiation of effector lymphocytes either to improve
TIL capacity or to encourage TILhoming to tumours. Thepossible
exploitation oftechniques directed at newly discovered angiogenic
factors controlling tumour neovasculature represents an exciting
potential therapy (Baillie et al, 1995).
Tumour cells themselves may also be transduced with cytokine
and cytokine receptor genes to render them suitably immunogenic.
The gastrointestinal tract represents a unique portal forpotential
gene therapy, although new techniques ofdelivery, such as the use
of liposomal carriers, biodegradable microspheres and attenuated
Salmonella spp. carriers, are required for consistent gene expres-
sion in such a hostile environment.
The Fearon-Vogelstein model of colorectal tumorigenesis
(Fearon and Vogelstein, 1990) represents a challenge to modify the
natural history of colonic tumours and premalignant disease
through genetic intervention, as it is recognized that many
mammalian cells have the cellular machinery required for
successful integration of foreign genetic material into the parent
genome (Capecchi, 1989). Many ofthese approaches in colorectal
cancer are still theoretical, and much workneeds to be done before
they can become clinically valuable. The approach to increase the
immunogenicity rather than the antigenicity of the tumour cell
itself and to abrogate a tumour-induced immunosuppressive
microenvironment remains a significant challenge for the future.
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